Wegovy label adds a never-share warning for the FlexTouch pen

The prescribing information for Wegovy, revised June 2026, adds a new warning section, 5.11, titled "Never Share WEGOVY FlexTouch Between Patients." It applies to the WEGOVY FlexTouch pen, a 9.6 mg/3 mL (3.2 mg/mL) solution built for multiple uses, which delivers four separate 2.4 mg/0.75 mL doses from one pen ^[1][2]. The label states the pen must not be shared "even if the needle is changed" ^[1][2].

This is one of several dosage-form details spelled out in the June 2026 label. Wegovy injection also comes in single-dose pens and single-dose syringes at strengths from 0.25 mg up to 2.4 mg, plus a 7.2 mg single-dose pen sold as Wegovy HD, and the drug is separately available as oral tablets in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths ^[1][2]. The FlexTouch multi-dose pen is distinct from all of these because it is meant to be used repeatedly by one person over time to deliver the standard 2.4 mg weekly maintenance dose, rather than discarded after a single injection ^[1][2].

The new warning sits among a list of other label changes tracked in the "Recent Major Changes" section, which also shows that a prior warning about suicidal behavior and ideation (section 5.10) was removed in the label, with DailyMed listing that removal as effective 02/2026 and the Novo Nordisk PDF listing it as 01/2026 ^[1][2]. The sources do not explain the reason for that discrepancy or for the removal itself.

Why it matters for patients

Sharing an injector pen between people carries a risk of transmitting bloodborne infections, even when a fresh needle is used, because the pen's internal mechanism can still be contaminated with blood or bodily fluid. The label's explicit instruction that the FlexTouch pen must never be shared, regardless of needle changes, gives patients and caregivers clear, written guidance that did not previously appear in this form ^[1][2]. This is especially relevant for households where more than one person may be using Wegovy or where a pen is being used by a caregiver on behalf of someone else, since the multi-dose design of the FlexTouch pen, which holds four weekly doses, differs from the single-dose pens and syringes where each device is discarded after one injection ^[1][2].

The label does not describe any specific reported cases tied to this warning, so it is not known from these sources whether the change followed a particular safety incident or was added as a precautionary measure tied to the pen's multi-dose design. Patients using the FlexTouch formulation may want to be aware of this distinction when discussing proper use and storage of the device with a pharmacist or prescriber, though the sources do not provide instructions beyond the core warning itself.

The label changes also touch on other areas patients may want to note. An acute kidney injury warning tied to volume depletion was added in August 2025, and a warning about severe gastrointestinal adverse reactions, including a caution against use in patients with severe gastroparesis, was added in October 2025 ^[1][2]. Both remain part of the June 2026 label alongside the new pen-sharing warning ^[1][2].

What happens next

The sources reviewed do not indicate any further scheduled changes to the Wegovy label beyond the June 2026 revision. The "Recent Major Changes" table lists dated updates through June 2026 for dosage and administration, warnings, and indications, but does not preview future changes ^[1][2]. Patients and caregivers can check the full prescribing information and medication guide, both referenced in the label, for the complete set of instructions tied to the FlexTouch pen and other dosage forms ^[1][2].